Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Dapagliflozin vs Dapagliflozin-Finerenone Combination on Albuminuria in CKD and T2DM
NCT07598864Phase 3Not yet recruiting
- Sponsor
- Chattogram Medical College
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of finerenone in diabetic nephropathy (DN) (2 arms), sponsored by Chattogram Medical College. Primary endpoint: Change in urinary albumin-to-creatinine ratio at 8 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
finerenone
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT07598864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07598864.